Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol.
Nishina T, Numata J, Nishina K, Yoshida-Tanaka K, Nitta K, Piao W, Iwata R, Ito S, Kuwahara H, Wada T, Mizusawa H, Yokota T. Nishina T, et al. Among authors: nishina k. Mol Ther Nucleic Acids. 2015 Jan 13;4(1):e220. doi: 10.1038/mtna.2014.72. Mol Ther Nucleic Acids. 2015. PMID: 25584900 Free PMC article.
DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing.
Nishina K, Piao W, Yoshida-Tanaka K, Sujino Y, Nishina T, Yamamoto T, Nitta K, Yoshioka K, Kuwahara H, Yasuhara H, Baba T, Ono F, Miyata K, Miyake K, Seth PP, Low A, Yoshida M, Bennett CF, Kataoka K, Mizusawa H, Obika S, Yokota T. Nishina K, et al. Among authors: nishina t. Nat Commun. 2015 Aug 10;6:7969. doi: 10.1038/ncomms8969. Nat Commun. 2015. PMID: 26258894 Free PMC article.
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Sakamoto Y, Nishina T, Inaki K, Kuwahara Y, Wada N, Suto F, Arita T, Sugihara M, Tsuchihashi Z, Saito K, Kojima A, Yamaguchi K. Shitara K, et al. Among authors: nishina t. Nat Med. 2024 May 14. doi: 10.1038/s41591-024-02992-x. Online ahead of print. Nat Med. 2024. PMID: 38745009
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study.
Kato K, Kojima T, Hara H, Tsuji A, Yasui H, Muro K, Satoh T, Ogata T, Ishihara R, Goto M, Baba H, Nishina T, Han S, Iwakami K, Yatsuzuka N, Doi T. Kato K, et al. Among authors: nishina t. Esophagus. 2024 Apr 12. doi: 10.1007/s10388-024-01053-z. Online ahead of print. Esophagus. 2024. PMID: 38607538
Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study.
Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, Nishina T, Yasui H, Kanazawa A, Ando K, Horita Y, Goto M, Okano N, Moriwaki T, Satoh T, Tsuji A, Yamashita K, Asano C, Abe Y, Nomura S, Yoshino T. Yuki S, et al. Among authors: nishina t. Clin Colorectal Cancer. 2024 Jan 18:S1533-0028(24)00003-3. doi: 10.1016/j.clcc.2024.01.003. Online ahead of print. Clin Colorectal Cancer. 2024. PMID: 38331650 Free article.
Prospective observational study of zinc deficiency symptoms during first-line chemotherapy for gastric and colorectal cancer.
Sakaguchi C, Nishina T, Kono Y, Hino K, Asagi A, Ohno Y, Kajiwara T, Nadano S, Yamashita N, Tohyama M, Hyodo I, Okada H, Otsuka M. Sakaguchi C, et al. Among authors: nishina t. J Gastrointest Oncol. 2023 Dec 31;14(6):2384-2394. doi: 10.21037/jgo-23-517. Epub 2023 Nov 23. J Gastrointest Oncol. 2023. PMID: 38196526 Free PMC article.
421 results